As the battle intensifies among AbbVie, Johnson & Johnson, AstraZeneca, and BeiGene in the BTK inhibitor market, Eli Lilly stands out by forging a new direction in the landscape of blood cancer drugs. Just at the beginning of this month, the FDA granted accelerated approval to Lilly’s Jaypirca. This approval is significant for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have undergone at least two prior lines of therapy. What sets Jaypirca apart is that, as a BTK inhibitor, it is now authorized for use after treatment with both a BTK inhibitor and a BCL-2 inhibitor.
Nearly a year since Jaypirca secured its initial ap...
